The latest report revealed the radiological findings of 89Zr-DFO-durvalumab PET/CT in 33 patients with recurrent or metastatic HNSCC before durvalumab (anti-PD-L1 antibody) treatment [98]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.